OMER News and Press, Omeros Corporation From 11/03/22

Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology (ASH) Annual Meeting, which will be held from December 10-13, 2022 in New Orle...

Summary FDA appeal decision by OND of Narsoplimab for the treatment of patients with HSCT-TMA should be coming in the next few months. Results from the phase 3 ARTEMIS-IGAN study, using Narsoplimab for the treatment of patients with IgA Nephropathy are expected in mid-2023. Re...

Summary Omeros stock has been drifting with a downward bias since it reported its Q4 2021 earnings. Its problem stems from its protracted delay in getting FDA approval of its narsoplimab in treatment of HSCT-TMA. Omeros' recent deal works to maintain its liquidity without shar...

-- Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA – Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly ...

The shares of commercial-stage biopharma, Omeros Corporation ( NASDAQ: OMER ) fell ~11% in the morning hours Thursday after the company reported data from a clinical trial involving critically ill COVID-19 patients who received its experimental therapy narsoplimab in addit...

-- Reduction in Mortality Risk with Narsoplimab -- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysis in the randomized patient population shows that ...

Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed in the narsoplimab arm of the I-SPY COVID Tria...

Summary Today, we revisit Arbutus Biopharma Corporation for the first time in almost a year. An interesting 'sum of the parts' story seems to be emerging around the company and the stock. An investment analysis follows in the paragraphs below. "I could easily for...

Omeros' lead therapy, narsoplimab in treatment of High-Risk HSCT-TMA, has fumbled repeatedly in front of the FDA. The FDA's latest chapter in this ongoing saga spells progress with a likely high dose of delay. Omeros' potential expanded delay could challenge its ongoing liquidity....

Omeros ( NASDAQ: OMER ) said on Wednesday that the United States Food and Drug Administration had given an interim response to the its formal dispute resolution request that it had submitted in June, appealing the decision by the agency review division to issue a comp...